Thermo Fisher Scientific (NYSE:TMO) Upgraded to Buy at StockNews.com

Thermo Fisher Scientific (NYSE:TMO – Get Rating) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other analysts also recently issued reports on TMO. SVB Leerink increased their price objective on shares of Thermo Fisher Scientific from $620.00 to $630.00 and gave the company an “outperform” rating in a research report on Thursday, February 2nd. Barclays lifted their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock an “overweight” rating in a research note on Thursday, February 2nd. Morgan Stanley raised their target price on Thermo Fisher Scientific from $613.00 to $670.00 and gave the company an “overweight” rating in a research note on Thursday, February 2nd. Deutsche Bank Aktiengesellschaft started coverage on Thermo Fisher Scientific in a research note on Tuesday, December 13th. They issued a “buy” rating and a $620.00 price target on the stock. Finally, Cowen lifted their price objective on Thermo Fisher Scientific from $690.00 to $711.00 and gave the stock an “outperform” rating in a report on Thursday, February 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $647.00.

Thermo Fisher Scientific Price Performance

TMO opened at $547.34 on Friday. The company has a 50 day moving average of $565.91 and a two-hundred day moving average of $545.06. Thermo Fisher Scientific has a 52-week low of $475.77 and a 52-week high of $618.35. The company has a quick ratio of 1.15, a current ratio of 1.48 and a debt-to-equity ratio of 0.66. The company has a market cap of $210.96 billion, a P/E ratio of 31.05, a P/E/G ratio of 1.88 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last announced its quarterly earnings results on Wednesday, February 1st. The medical research company reported $5.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.19 by $0.21. Thermo Fisher Scientific had a return on equity of 21.42% and a net margin of 15.47%. The firm had revenue of $11.45 billion during the quarter, compared to the consensus estimate of $10.41 billion. During the same period in the prior year, the firm earned $6.54 EPS. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, analysts expect that Thermo Fisher Scientific will post 23.72 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction that occurred on Friday, February 10th. The stock was sold at an average price of $569.18, for a total transaction of $11,383,600.00. Following the sale, the chief executive officer now directly owns 128,705 shares in the company, valued at approximately $73,256,311.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 1,600 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $571.96, for a total transaction of $915,136.00. Following the sale, the chief executive officer now owns 128,705 shares of the company’s stock, valued at approximately $73,614,111.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, February 10th. The stock was sold at an average price of $569.18, for a total value of $11,383,600.00. Following the transaction, the chief executive officer now directly owns 128,705 shares in the company, valued at $73,256,311.90. The disclosure for this sale can be found here. Insiders have sold a total of 30,100 shares of company stock worth $16,966,971 over the last quarter. 0.43% of the stock is owned by company insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several large investors have recently made changes to their positions in the business. Grayhawk Investment Strategies Inc. acquired a new position in Thermo Fisher Scientific in the second quarter worth approximately $26,000. Lowe Wealth Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 160.0% during the 3rd quarter. Lowe Wealth Advisors LLC now owns 52 shares of the medical research company’s stock worth $26,000 after acquiring an additional 32 shares in the last quarter. New Millennium Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $29,000. OLD Mission Capital LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $31,000. Finally, Richard W. Paul & Associates LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $34,000. Institutional investors own 85.92% of the company’s stock.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.